Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 4/20 | 0.33 |
| ▸ | RAB9A | P51151 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL977800 | 0.83 | MCHR1 (0.37) | KDM4ETP53NPC1RAB9AALDH1A1 | |
| SCHEMBL974506 | 0.75 | HDAC1 (0.33) | KDM4ETP53NPC1RAB9AALDH1A1 | |
| SCHEMBL974212 | 0.74 | KDM4E (0.36) | KDM4ETP53NPC1RAB9AALDH1A1 | |
| SCHEMBL13633339 | 0.73 | NPC1 (0.52) | KDM4ETP53NPC1RAB9AALDH1A1 | |
| SCHEMBL423547 | 0.72 | NPC1 (0.58) | KDM4ETP53NPC1RAB9AALDH1A1 | |
| SCHEMBL10222603 | 0.72 | KDM4E (0.44) | KDM4ETP53NPC1RAB9AALDH1A1 | |
| SCHEMBL976088 | 0.70 | MCHR1 (0.36) | KDM4ENPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL12335783 | 0.70 | KDM4E (0.36) | KDM4ETP53NPC1RAB9AALDH1A1 | |
| SCHEMBL1500151 | 0.70 | PIK3CG (0.55) | KDM4ETP53NPC1RAB9AALDH1A1 | |
| SCHEMBL8814958 | 0.70 | KDM4E (0.68) | KDM4ETP53NPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067646-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. | 2024-02-29 | — | — | US | disclosed |
| US-20230310651-A1 | METHODS FOR MODULATING RNA SPLICING | PTC THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | US | disclosed |
| EP-4249472-A2 | METHODS FOR MODULATING RNA SPLICING | PTC Therapeutics, Inc. (US) | 2023-09-27 | — | — | EP | disclosed |
| US-20230272367-A1 | METHODS FOR MODULATING RNA SPLICING | PTC THERAPEUTICS, INC. (US) | 2023-08-31 | — | — | US | disclosed |
| EP-3644996-B1 | METHODS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2023-07-26 | — | — | EP | disclosed |
| EP-3310169-B1 | METHODS FOR MODULATING RNA SPLICING | PTC THERAPEUTICS INC (US) | 2023-05-17 | — | — | EP | disclosed |
| US-11602567-B2 | Methods for modulating RNA splicing | PTC THERAPEUTICS, INC. (US) | 2023-03-14 | — | — | US | disclosed |
| EP-3082820-B1 | METHODS FOR MODULATING THE AMOUNT OF RNA TRANSCRIPTS | PTC THERAPEUTICS INC (US) | 2022-07-20 | — | — | EP | disclosed |
| US-11382918-B2 | Methods for treating Huntington's Disease | PTC THERAPEUTICS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20210069350-A1 | METHODS FOR MODULATING RNA SPLICING | PTC THERAPEUTICS, INC. (US) | 2021-03-11 | — | — | US | disclosed |
| EP-2809322-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC Therapeutics, Inc. (US) | 2014-12-10 | — | — | EP | disclosed |
| EP-2797592-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC Therapeutics, Inc. (US) | 2014-11-05 | — | — | EP | disclosed |
| WO-2013142236-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2013-09-26 | — | — | WO | disclosed |
| EP-2235016-B1 | AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2013-09-18 | — | — | EP | disclosed |
| WO-2013130689-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2013-09-06 | — | — | WO | disclosed |
| WO-2013119916-A2 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2013-08-15 | — | — | WO | disclosed |
| WO-2013112788-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2013-08-01 | — | — | WO | disclosed |
| WO-2013101974-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2013-07-04 | — | — | WO | disclosed |
| US-8394820-B2 | N-azabicyclic carboxamide derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-03-12 | — | — | US | disclosed |
| US-20110009444-A1 | N-AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067646-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, GYS1 | KDM4E 2384/4885TP53 4877/4885NPC1 1156/4885 |
| US-20230272367-A1 | METHODS FOR MODULATING RNA SPLICING | RBM17, SNRPE, HNRNPM | KDM4E 1829/4885TP53 4515/4885NPC1 3722/4885 |
| US-20210069350-A1 | METHODS FOR MODULATING RNA SPLICING | RBM17, SNRPE, RBM3 | KDM4E 1422/4885TP53 4236/4885NPC1 4471/4885 |
| US-11602567-B2 | Methods for modulating RNA splicing | RBM17, SNRPE, RBM3 | KDM4E 1422/4885TP53 4236/4885NPC1 4471/4885 |
| US-20110009444-A1 | N-AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | XDH, NQO2, SLC28A2 | KDM4E 246/4885TP53 1859/4885NPC1 1025/4885 |
| US-20230310651-A1 | METHODS FOR MODULATING RNA SPLICING | RBM17, SNRPE, RBM3 | KDM4E 1422/4885TP53 4236/4885NPC1 4471/4885 |
| US-11382918-B2 | Methods for treating Huntington's Disease | HTT, HYPK, PARK7 | KDM4E 3963/4885TP53 3143/4885NPC1 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.